@article{09b80df45ca94be5aad74a5a2a9adc1a,
title = "Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma",
abstract = "The current study was undertaken to determine the maximum tolerated dose of recombinant interleukin-2 (rIL-2) that could be administered as a continuous infusion in conjunction with autologous lymphokine-activated killer (LAK) cells. All 55 patients in this study received a priming dose of rIL-2 of 1.0 mg/m2 per day given as a continuous infusion over 4.5 days. Patients later received (days 11-16) one of three doses of rIL-2 per day (1.0, 1.25, or 1.50 mg/m2) in conjunction with LAK cells given on days 11, 12, and 14. Because of unacceptable toxicity occurring early in the LAK cell phase of therapy at the rIL-2 dose level of 1.50 mg/m2, we concluded that the maximum tolerated dose of rIL-2 given as a continuous infusion with LAK cells is 1.25 mg/m2 per day. [J Natl Cancer Inst 82: 1397-1402, 1990]",
author = "Gaynor, {Ellen R.} and Weiss, {Geoffrey R.} and Margolin, {Kim A.} and Aronson, {Frederick R.} and Mario Sznol and Paul Demchak and Grima, {Kathleen M.} and Fisher, {Richard I.} and Boldt, {David H.} and Doroshow, {James H.} and Bar, {Michael H.} and Hawkins, {Michael J.} and Mier, {James W.} and Geralyn Caliendo",
note = "Funding Information: Received June II, 1990; accepted June 12, 1990. Supported by Public Health Service contracts N01CM-73702, N01CM-73703, N01CM-73704, N01CM-73705, N01CM-73706, and N01CM-73707 from the Division of Cancer Treatment, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services (DHHS), and Clinical Research Center Grants M01-RR0O054 and M01-RR00079 from the Division of Research Resources, NIH, DHHS, to Tufts University School of Medicine and the University of California, San Francisco. Presented in part at the annual meeting of the American Association of Cancer Research, San Francisco, Calif, May 1989. E. R. Gaynor, R. I. Fisher, Loyola University Medical Center, Maywood, 111. G. R. Weiss, D. H. Boldt, University of Texas Health Science Center, San Antonio, Tex. K. A. Margolin, J. H. Doroshow, City of Hope Cancer Research Center, Duarte, Calif. F. R. Aronson, M. H. Bar, University of California, San Francisco, Calif. M. Sznol, M. J. Hawkins, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md. P. Demchak, J. W. Mier, Tufts-New England Medical Center, Boston, Mass. K. M. Grima, G. Caliendo, Albert Einstein CancerCenter/Montefiore Medical Center, New York, NY. Correspondence to: Ellen R. Gaynor, fvt.D., Section of Hematology/ Oncology, Loyola University Stritch School of Medicine, 2160 S. First Ave., Maywood, IL 60153.",
year = "1990",
month = sep,
day = "5",
doi = "10.1093/jnci/82.17.1397",
language = "English (US)",
volume = "82",
pages = "1397--1402",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "17",
}